無料プレビュー

Immunovant, Inc. (IMVT) · NASDAQ Global Select

プロフィール

Immunovant, Inc. is a clinical-stage immunology company developing IMVT-1402, a monoclonal antibody that inhibits the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies in autoimmune diseases. The company is advancing potentially registrational trials of IMVT-1402 across six indications: Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren's disease, and cutaneous lupus erythematosus. Immunovant is a majority-owned subsidiary of Roivant Sciences Ltd and operates through a collaborative development m

主要指標

株価: $30.26 (-5.56%)
時価総額: 62億ドル
PER（今期予想）: -10.3
PBR: 8.5
配当利回り: —
52週レンジ: $16.59 – $45.42
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-09 · 更新: 2026-10-09